Stock listing
Frankfurt:I5X Precigen, Inc. Aktie
German listing (Frankfurt) of Precigen, Inc. · home listing NASDAQ:PGEN
Follow Precigen, Inc. into a list and get an email when it puts out news.
Share price · FWB:I5X
€3.83 EUR +0.13 (+3.5%)
Close on Nov 20, 2026
- Day range
- €3.70 – €3.83 EURNov 20, 2026
- Market cap
- €1.37B EURAt the close on Nov 20, 2026 · price × 358.0M shares outstanding
- 52-week range
- €2.58 – €7.66 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €6,097 EURMedian day 28 shares · 28 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PGEN · Home | $4.21 USD | -0.06 (-1.4%) | 6,067,718 | $4.155 | $4.36 | $4.07 | $4.27 | Close on Nov 20, 2026 |
| Frankfurt:I5X | €3.83 EUR | +0.13 (+3.5%) | — | €3.70 | €3.83 | €3.70 | €3.70 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:I5X · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €3.575 | +0.022 | +0.6% | €3.651 | €3.693 | €3.567 | 1,000 | |
| €3.553 | -0.803 | -18.4% | €4.239 | €4.26 | €3.552 | 800 | |
| €4.356 | -0.219 | -4.8% | €4.543 | €4.623 | €4.351 | 3,500 | |
| €4.575 | +0.18 | +4.1% | €4.376 | €4.641 | €4.375 | 960 | |
| €4.395 | -1.359 | -23.6% | €4.74 | €4.759 | €4.395 | 600 | |
| €5.754 | +0.34 | +6.3% | €5.795 | €5.795 | €5.751 | 1,600 | |
| €5.414 | +0.067 | +1.3% | €5.399 | €5.424 | €5.38 | 600 | |
| €5.347 | +0.005 | +0.1% | €5.46 | €5.503 | €5.335 | 1,788 | |
| €5.342 | -0.153 | -2.8% | €5.382 | €5.425 | €5.331 | 0 | |
| €5.495 | -0.046 | -0.8% | €5.457 | €5.50 | €5.441 | 16,780 | |
| €5.541 | -0.161 | -2.8% | €5.675 | €5.696 | €5.532 | 718 | |
| €5.702 | -0.327 | -5.4% | €5.718 | €5.773 | €5.698 | 0 | |
| €6.029 | +0.238 | +4.1% | €6.095 | €6.097 | €5.943 | 0 | |
| €5.791 | +0.032 | +0.6% | €5.791 | €5.791 | €5.791 | 0 | |
| €5.759 | -0.413 | -6.7% | €5.759 | €5.759 | €5.759 | 0 | |
| €6.172 | -0.461 | -7.0% | €6.411 | €6.414 | €6.158 | 0 | |
| €6.633 | -0.006 | -0.1% | €6.499 | €6.672 | €6.379 | 150 | |
| €6.639 | +0.026 | +0.4% | €6.659 | €6.672 | €6.637 | 2,900 | |
| €6.613 | -0.252 | -3.7% | €6.706 | €6.744 | €6.516 | 0 | |
| €6.865 | +0.285 | +4.3% | €6.956 | €6.956 | €6.853 | 0 | |
| €6.58 | -0.005 | -0.1% | €6.687 | €6.71 | €6.55 | 600 | |
| €6.585 | -0.01 | -0.2% | €6.666 | €6.728 | €6.583 | 4,800 | |
| €6.595 | -0.277 | -4.0% | €6.599 | €6.60 | €6.586 | 400 | |
| €6.872 | -0.486 | -6.6% | €6.883 | €6.918 | €6.87 | 0 | |
| €7.358 | +0.126 | +1.7% | €7.478 | €7.496 | €7.038 | 4,546 | |
| €7.232 | -0.239 | -3.2% | €7.251 | €7.253 | €7.232 | 368 | |
| €7.471 | +0.474 | +6.8% | €7.645 | €7.658 | €7.461 | 0 | |
| €6.997 | +0.144 | +2.1% | €7.02 | €7.079 | €6.975 | 1,550 | |
| €6.853 | +0.133 | +2.0% | €6.806 | €6.858 | €6.805 | 0 | |
| €6.72 | -0.015 | -0.2% | €6.726 | €6.732 | €6.72 | 1,966 | |
| €6.735 | +0.312 | +4.9% | €6.735 | €6.735 | €6.735 | 4,868 | |
| €6.423 | -0.468 | -6.8% | €6.423 | €6.423 | €6.423 | 0 | |
| €6.891 | +0.234 | +3.5% | €6.891 | €6.891 | €6.891 | 0 | |
| €6.657 | -0.071 | -1.1% | €6.657 | €6.657 | €6.657 | 0 | |
| €6.728 | -0.015 | -0.2% | €6.728 | €6.728 | €6.728 | 0 | |
| €6.743 | +0.287 | +4.4% | €6.821 | €6.851 | €6.732 | 0 | |
| €6.456 | +0.449 | +7.5% | €6.503 | €6.89 | €6.456 | 198 | |
| €6.007 | +0.289 | +5.1% | €6.014 | €6.082 | €5.966 | 0 | |
| €5.718 | -0.125 | -2.1% | €5.805 | €5.833 | €5.698 | 0 | |
| €5.843 | +0.069 | +1.2% | €5.886 | €5.889 | €5.767 | 0 | |
| €5.774 | +0.194 | +3.5% | €5.708 | €5.84 | €5.688 | 28 | |
| €5.58 | -0.09 | -1.6% | €5.744 | €5.849 | €5.569 | 0 | |
| €5.67 | -0.223 | -3.8% | €5.636 | €5.689 | €5.588 | 289 | |
| €5.893 | -0.109 | -1.8% | €5.831 | €5.908 | €5.83 | 540 | |
| €6.002 | -0.081 | -1.3% | €6.002 | €6.002 | €6.002 | 0 | |
| €6.083 | +0.137 | +2.3% | €6.133 | €6.133 | €6.019 | 660 | |
| €5.946 | +0.036 | +0.6% | €5.962 | €5.973 | €5.907 | 0 | |
| €5.91 | +0.073 | +1.3% | €5.897 | €5.985 | €5.884 | 0 | |
| €5.837 | +0.124 | +2.2% | €5.849 | €5.871 | €5.759 | 1,505 | |
| €5.713 | -0.254 | -4.3% | €5.961 | €5.979 | €5.673 | 0 | |
| €5.967 | -0.176 | -2.9% | €6.079 | €6.085 | €5.887 | 3,200 | |
| €6.143 | -0.279 | -4.3% | €6.139 | €6.147 | €6.135 | 0 | |
| €6.422 | +0.258 | +4.2% | €5.972 | €6.518 | €5.965 | 950 | |
| €6.164 | +0.286 | +4.9% | €6.139 | €6.176 | €6.062 | 0 | |
| €5.878 | -0.30 | -4.9% | €5.995 | €6.078 | €5.869 | 0 | |
| €6.178 | +0.261 | +4.4% | €6.249 | €6.348 | €6.137 | 806 | |
| €5.917 | +0.159 | +2.8% | €6.111 | €6.149 | €5.917 | 0 |
- Ticker
- Frankfurt:I5X
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
Latest earnings call · Nov 4, 2026
Precigen (NASDAQ:PGEN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · May 13, 2026
Q1 2026 Earnings Presentation
Earnings · 21 slides
Latest news
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
Nov 4, 2026
Closed €3.55 (-18.4%) on Nov 5, 2026
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
Oct 28, 2026
Closed €5.41 (+1.3%) on Oct 29, 2026
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Sep 21, 2026
Closed €6.73 (-0.2%) on Sep 21, 2026
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
Aug 4, 2026
Closed €5.84 (+7.2%) on Aug 5, 2026
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Jul 21, 2026
Closed €4.46 (+4.0%) on Jul 21, 2026
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Jun 15, 2026
Closed €3.87 (+1.0%) on Jun 15, 2026
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Jun 11, 2026
Closed €3.37 (+6.2%) on Jun 11, 2026
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
May 30, 2026
Closed €3.67 (-3.5%) on Jun 1, 2026
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
May 27, 2026
Closed €3.56 (-2.0%) on May 27, 2026
Precigen, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 19 in the last 12 months · 171 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 15 calls with a replay · 15 with a transcript · latest Nov 4, 2026
- Decks
- 34 decks · latest May 13, 2026
Where Precigen, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PGEN · Home listing | NASDAQ | United States | USD |
| gettex:I5X | gettex | Germany | EUR |
| Lang & Schwarz:A2PZG1 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2PZG1 | LS Exchange | Germany | EUR |
| Tradegate:I5X | Tradegate | Germany | EUR |
| BOATS:PGEN | BOATS | United States | USD |
| Frankfurt:I5X · This page | Frankfurt | Germany | EUR |
| BX Swiss:I5X | BX Swiss | Switzerland | CHF |
| Dusseldorf:I5X | Dusseldorf | Germany | EUR |
| Hamburg:I5X | Hamburg | Germany | EUR |
| Munich:I5X | Munich | Germany | EUR |
| Stuttgart:I5X | Stuttgart | Germany | EUR |
Valuation
P/E 61.9× against a median of 22.9×: 9th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.56B USD
- P/E
- 61.9×
- EV/sales
- 9.9×
- EV/EBITDA
- 40.9×
- Price/book
- 18.0×
- Gross margin
- 91.0%
- Operating margin
- 21.4%
- Net margin
- 15.6%
- Debt to equity
- 1.1×
- Beta vs S&P 500
- 1.46
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Precigen, Inc. · NASDAQ:PGEN | US$1.51B | US$1.56B | 61.9× | 9.9× | 40.9× | 18.0× | 15.6% | 1.1× | 1.46 |
| Fujian Cosunter Pharmaceutical Co., Ltd. Class A · SZSE:300436 | US$1.57B | US$1.47B | n/a | 22.8× | n/a | 12.7× | −48.9% | 0.2× | n/a |
| Shanghai Shyndec Pharmaceutical Co., Ltd. Class A · SSE:600420 | US$1.56B | US$938.9M | 22.9× | 0.8× | n/a | 0.8× | 5.7% | 0.0× | n/a |
| ANI Pharmaceuticals, Inc. · NASDAQ:ANIP | US$1.56B | US$1.42B | 13.3× | 1.4× | 5.7× | 2.4× | 11.2% | 0.5× | 0.34 |
| Zhejiang CONBA Pharmaceutical Co., Ltd. Class A · SSE:600572 | US$1.55B | US$1.42B | 22.6× | 1.4× | n/a | 1.4× | 6.7% | 0.0× | n/a |
| Tibet Cheezheng Tibetan Medicine Co., Ltd. Class A · SZSE:002287 | US$1.53B | US$1.15B | 16.2× | 3.4× | n/a | 2.0× | 28.2% | 0.0× | n/a |
| Yifan Pharmaceutical Co., Ltd. Class A · SZSE:002019 | US$1.52B | US$1.61B | 32.6× | 2.2× | n/a | 1.1× | 6.3% | 0.2× | n/a |
| Corona Remedies Limited · NSE:CORONA | US$1.49B | US$1.48B | 74.8× | 9.8× | 46.7× | 17.2× | 13.2% | 0.0× | n/a |
| Sunshine Lake Pharma Co., Ltd. Class H · HKEX:6887 | US$1.48B | US$1.48B | 36.1× | 2.0× | 9.0× | 2.5× | 5.7% | 0.4× | n/a |
| Zhejiang Medicine Co., Ltd. Class A · SSE:600216 | US$1.47B | US$975.3M | 15.5× | 0.8× | n/a | 0.8× | 7.5% | 0.0× | n/a |
| Yantai Dongcheng Biochemicals Co., Ltd. Class A · SZSE:002675 | US$1.47B | US$1.41B | 46.5× | 3.6× | n/a | 2.2× | 8.0% | 0.1× | n/a |
| Median of the others | US$1.53B | US$1.42B | 22.9× | 2.1× | 9.0× | 2.1× | 7.1% | 0.1× | 0.34 |
Forecasts
2 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 13.67 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.24 · 4 analysts
- Revenue, year to Dec 2026
- 240.2M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Helen Sabzevari | President and CEO |
| Harry Thomasian | Chief Financial Officer |
| Rutul R. Shah | Chief Operating Officer |
| Donald Lehr | Chief Legal Officer |
| Steven M. Harasym | Investor Relations |
| Amy R. Lankford | SVP, Global Head of Regulatory Affairs |
| Bryan T. Butman | SVP, Head of CMC |
| Douglas E. Brough | SVP, Head of Research |
| Gaetano Bonifacio | SVP, Head of Development |
| Phil Tennant | Chief Commercial Officer |
| Randal J. Kirk | Executive Chairman |
Board
| Director | Role |
|---|---|
| Randal J. Kirk | Executive Chairman |
| Cesar L. Alvarez | Director |
| Fred Hassan | Director |
| Helen Sabzevari | President and CEO |
| James S. Turley | Director |
| Jeffrey B. Kindler | Director |
| Nancy H. Agee | Director |
| Steven R. Frank | Director |
| Vinita D. Gupta | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Precigen (NASDAQ:PGEN) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q1 2026 Earnings Call | Wed, May 13, 2026 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q4 2025 Earnings Call | Wed, Mar 25, 2026 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q4 2024 Earnings Call | Wed, Mar 19, 2025 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q4 2023 Earnings Call | Tue, Mar 19, 2024 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q2 2023 Earnings Call | Wed, Aug 09, 2023 · 8:30 AM ET | Replay |
| Precigen (NASDAQ:PGEN) Q4 2022 Earnings Call | Wed, May 10, 2023 · 8:00 AM ET | Replay |
All 15 calls
| Call | When | Status |
|---|---|---|
| Precigen (NASDAQ:PGEN) Q1 2023 Earnings Call | Wed, May 10, 2023 · 8:00 AM ET | Replay |
| Precigen (NASDAQ:PGEN) Q3 2022 Earnings Call | Wed, Nov 09, 2022 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 4:30 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 4:05 PM ET | Replay |
| Precigen (NASDAQ:PGEN) Q4 2020 Earnings Call | Mon, Mar 01, 2021 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −16.5% |
| Q2 2026 | Aug 4, 2026 · After close | +5.5% |
| Q1 2026 | May 13, 2026 · After close | +10.8% |
| Q4 2025 | Mar 9, 2026 | +5.7% |
| Q3 2025 | Nov 13, 2025 · After close | +25.6% |
| Q2 2025 | Aug 12, 2025 · After close | +6.1% |
| Q1 2025 | May 14, 2025 · After close | +2.3% |
| Q4 2024 | Mar 19, 2025 | +7.8% |
| Q3 2024 | Nov 14, 2024 · After close | −6.8% |
| Q2 2024 | Aug 14, 2024 · After close | −4.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +5.1% |
| Q4 2023 | Mar 19, 2024 · After close | 0.0% |
| Q3 2023 | Nov 9, 2023 · After close | −13.5% |
| Q2 2023 | Aug 9, 2023 · Before open | +6.9% |
| Q1 2023 | May 10, 2023 · Before open | −4.0% |
| Q4 2022 | Mar 6, 2023 · After close | +17.4% |
| Q3 2022 | Nov 9, 2022 · After close | +21.1% |
| Q2 2022 | Aug 8, 2022 · After close | +12.7% |
| Q1 2022 | May 9, 2022 · After close | +12.2% |
| Q4 2021 | Mar 1, 2022 · Before open | −4.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2026 Earnings Presentation | Earnings | 21 slides | May 13, 2026 |
| Corporate Update (August 2025) | Corporate update | 24 slides | Aug 18, 2025 |
| 39th Annual J.P. Morgan Healthcare Conference (January 2021) | Conference | 23 slides | Jan 13, 2021 |
| Q2 2020 Earnings Presentation | Earnings | 13 slides | Aug 10, 2020 |
| Q1 2020 Earnings Presentation | Earnings | 14 slides | May 6, 2020 |
| Q4 2019 Earnings Presentation | Earnings | 12 slides | Mar 2, 2020 |
| Intrexon — 38th Annual J.P. Morgan Healthcare Conference (January 2020) | Conference | 24 slides | Jan 15, 2020 |
| Intrexon — Corporate Update (November 2019) | Corporate update | 14 slides | Nov 12, 2019 |
| Intrexon — Q2 2019 Earnings Presentation | Earnings | 10 slides | Aug 8, 2019 |
| Intrexon — Corporate Update (May 2019) | Corporate update | 26 slides | May 9, 2019 |
All 34 decks
Financings
| Raise | Date |
|---|---|
| Private placement of 8.00% Series A Convertible Perpetual Preferred Stock and warrants Announced: US$79M · Warrants at US$0.75 Buyers: Patient Capital Management (led the private placement through affiliates); Bill Miller; Randal J. Kirk Insiders: Randal J. Kirk, executive chairman of the board of directors, participated Use of proceeds: Working capital and general corporate purposes | Dec 27, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.68M | 3.92M | 6.22M | 26.9M | 14.3M | 32.0M | 90.7M | 151.2M | 231.0M | 190.9M |
| Cost of revenue | 6.10M | 4.27M | 6.12M | 6.34M | 53.7M | 44.8M | 5.37M | 63.3M | 33.3M | 37.7M |
| Gross profit | 3.59M | -342.0K | 106.0K | 20.6M | -39.4M | -12.8M | 26.6M | 97.3M | 168.2M | 129.3M |
| Research and development | 41.3M | 53.1M | 48.6M | 47.2M | 47.9M | 39.4M | 39.4M | 404.6M | 143.2M | 112.1M |
| Selling, general and administrative | 70.1M | 41.3M | 40.4M | 48.0M | 74.1M | 91.7M | 100.8M | 137.8M | 146.1M | 142.3M |
| Operating income | -110.5M | -135.0M | -99.8M | -75.7M | -91.9M | -86.3M | -86.3M | -505.6M | -137.9M | -125.2M |
| Depreciation and amortization | 3.20M | 4.53M | 6.67M | 10.8M | 13.8M | 17.5M | 24.9M | 33.1M | 31.1M | 24.6M |
| EBITDA | -107.3M | -130.5M | -93.1M | -65.0M | -78.2M | -68.8M | -61.4M | -472.5M | -106.7M | -100.6M |
| Interest expense | 3.87M | 6.00K | 468.0K | 6.77M | 18.8M | 18.4M | 18.2M | 8.53M | 611.0K | 861.0K |
| Income before tax | -250.6M | -128.0M | -96.4M | -80.0M | -111.0M | -104.5M | -171.3M | -395.9M | -78.4M | -194.2M |
| Income tax | 3.00K | -1.79M | -458.0K | -189.0K | -160.0K | -82.0K | -930.0K | -15.4M | 2.07M | -3.88M |
| Net income | -250.6M | -126.2M | -95.9M | 28.3M | -92.2M | -170.5M | -322.3M | -509.3M | -117.0M | -186.6M |
| Earnings per share, basic | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 | -1.02 | -2.09 | -3.93 | -0.98 | -1.58 |
| Earnings per share, diluted | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 | -1.02 | -2.09 | -3.93 | -0.98 | -1.58 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 30.2M | 29.5M | 7.58M | 4.86M | 36.4M | 51.8M | 65.8M | 96.9M | 68.1M | 62.6M |
| Short-term investments | 67.6M | 68.4M | 55.3M | 51.1M | 72.2M | 48.3M | 9.26M | 119.6M | 6.27M | 174.6M |
| Receivables | 3.92M | 926.0K | 902.0K | 978.0K | 1.34M | 16.5M | 20.6M | 21.2M | 19.8M | 21.6M |
| Inventory | 9.58M | 0 | 1 | 287.0K | 326.0K | 11.4M | 16.1M | 21.4M | 20.5M | 21.1M |
| Current assets | 115.2M | 102.4M | 68.8M | 118.2M | 156.6M | 148.9M | 234.6M | 285.5M | 154.0M | 315.2M |
| Property, plant and equipment | 13.8M | 13.8M | 7.11M | 7.33M | 8.60M | 34.9M | 44.0M | 86.9M | 112.7M | 64.7M |
| Goodwill | 15.2M | 19.1M | 26.6M | 36.9M | 37.6M | 54.4M | 54.1M | 93.6M | 93.8M | 157.2M |
| Total assets | 155.5M | 145.3M | 151.0M | 216.0M | 359.9M | 314.6M | 455.8M | 716.2M | 846.9M | 949.1M |
| Accounts payable | 12.0M | 3.53M | 1.73M | 4.07M | 3.11M | 4.60M | 5.53M | 12.0M | 8.70M | 8.48M |
| Current liabilities | 37.3M | 21.5M | 23.0M | 78.6M | 34.6M | 42.1M | 122.9M | 61.6M | 80.2M | 94.6M |
| Long-term debt | 93.2M | 0 | 0 | 179.9M | 171.5M | 186.3M | 211.2M | 7.54M | 7.56M | |
| Total debt | 93.2M | 0 | 7.10M | 86.4M | 179.9M | 171.9M | 218.0M | 211.7M | 8.04M | 7.95M |
| Total liabilities | 134.6M | 78.5M | 32.5M | 89.7M | 252.5M | 247.4M | 384.1M | 337.5M | 300.3M | 379.8M |
| Shareholders' equity | 20.9M | 38.5M | 118.5M | 126.3M | 107.3M | 67.2M | 71.7M | 362.9M | 533.6M | 560.2M |
| Shares outstanding | 353.9M | 292.9M | 248.9M | 208.2M | 206.7M | 187.7M | 163.3M | 160.0M | 122.1M | 118.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -87.8M | -68.2M | -66.9M | -65.0M | -55.8M | -77.0M | -135.9M | -124.2M | -103.7M | -49.0M |
| Capital spending | -2.00M | -8.58M | -1.54M | -4.92M | -7.25M | -7.53M | -37.9M | -41.6M | -46.7M | -31.6M |
| Free cash flow | -89.8M | -76.8M | -68.5M | -70.0M | -63.0M | -84.5M | -173.8M | -165.8M | -150.4M | -80.6M |
| Cash from investing | -1.53M | -20.7M | -3.09M | 226.4M | -74.5M | 27.8M | 86.9M | -151.2M | 104.3M | -28.4M |
| Cash from financing | 90.0M | 110.6M | 29.6M | -155.3M | 121.2M | 32.7M | 8.14M | 309.8M | 4.28M | 12.1M |
| Dividends paid | -7.73M | -42.0M | ||||||||
| Share buybacks | -2.20M | 0 | 0 | 1.00K | 608.0K | 35.1M | 313.0K | 2.34M | -518.0K | -518.0K |
| Change in cash | 717.0K | 21.7M | -40.7M | 5.25M | -8.91M | -16.2M | -41.7M | 34.6M | 5.95M | -66.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 31, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 24, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 31, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 30, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 5, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 23, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 10, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2026 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Dec 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 23, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 22, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 17, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 17, 2025 | Financing | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 26, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 19, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 18, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | May 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 16, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| PRE 14A · Preliminary proxy statement | May 6, 2025 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 19, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 16, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 30, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 26, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Nov 7, 2024 | Current report | SEC |
| 8-K · Current report | Oct 10, 2024 | Current report | SEC |
| 8-K · Current report | Sep 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 30, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 9, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Aug 8, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Aug 6, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 5, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Precigen, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 358,549,980
- Fully diluted
- 358,549,980
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 358,549,980 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 358,549,980 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Fred Hassan Other companies: Recursion Pharmaceuticals, Inc. (Director · Since Oct 31, 2026); EyePoint, Inc. (Director · Since at least Sep 3, 2024); Cocrystal Pharma, Inc. (Director · Since at least Apr 20, 2023); BridgeBio Pharma, Inc. (Director · Since at least Aug 17, 2021); Prometheus Biosciences Inc (Director · May 14, 2021 – Jun 16, 2023 · Past); Time Warner Inc (Director · Jun 1, 2016 – Jun 14, 2018 · Past); Amgen Inc. (Director · Jul 28, 2015 – May 5, 2020 · Past) | Director · Since at least Jun 30, 2016 |
| Nancy Howell Agee Other companies: Atlantic Union Bankshares Corporation (Director · Since at least Apr 1, 2024); RGC Resources Inc. (Director · Since at least Jan 3, 2006); American National Bankshares Inc (Director · Apr 1, 2019 – Apr 1, 2024 · Past); Healthcare Realty Trust Incorporated (Director · Feb 17, 2016 – May 20, 2025 · Past); HomeTown Bankshares Corporation (Director · May 1, 2012 – Mar 9, 2017 · Past) | Director · Since at least Jul 5, 2024 |
| Dean Mitchell Other companies: Praxis Precision Medicines, Inc. (Chairman of the Board · Since at least Oct 15, 2020); Theravance Biopharma, Inc. (Director · Since at least Apr 30, 2019); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); ImmunoGen Inc (Director · Mar 31, 2019 – Feb 12, 2024 · Past) | Director · Mar 8, 2020 – Mar 14, 2024 · Past |
| Andrew J Last Other companies: Insight Molecular Diagnostics Inc. (Director · Since at least Dec 30, 2015); Bio-Rad Laboratories, Inc. (EVP, Chief Operating Officer · Apr 22, 2019 – Sep 6, 2024 · Past); Affymetrix Inc (EVP, Chief Operating Officer · Feb 24, 2010 – Mar 31, 2016 · Past) | Chief Operating Officer · Aug 29, 2016 – Nov 13, 2017 · Past |
| James S. Turley Other companies: Northrop Grumman Corporation (Director · Since at least Feb 19, 2015); Emerson Electric Company (Director · Since at least Jul 10, 2013); Citigroup, Inc. (Director · Since at least Jul 4, 2013) | Director · Since at least Apr 16, 2014 |
| Jeffrey Kindler Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jan 8, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2024); Perrigo Company plc (Director · May 14, 2024 – May 14, 2025 · Past) | Director · Since at least Dec 28, 2023 |
| Nir Nimrodi Other companies: Evogene Ltd. (Chairperson of the Board · Since at least Mar 18, 2026); Odysight.ai Inc. (Director · Since at least Feb 10, 2025) | Chief Business Officer · Mar 17, 2014 – Jan 4, 2019 · Past |
| Olivier R. Jarry Other companies: OS Therapies Incorporated (Chief Executive Officer · Since at least Oct 28, 2024); DarioHealth Corp. (See Remarks · Aug 30, 2018 – Jan 28, 2020 · Past) | SVP--Consumer Sector · Jun 11, 2015 – Jun 11, 2015 · Past |
| Randal J. Kirk Other companies: Alaunos Therapeutics, Inc. (Director · Dec 30, 2011 – Oct 5, 2018 · Past); Halozyme Therapeutics, Inc. (Director · Nov 14, 2011 – Jul 24, 2017 · Past) | Executive Chairman · Since at least Aug 7, 2013 |
| Robert B Shapiro Other companies: NYSE Euronext Inc (Director · Apr 3, 2007 – Apr 27, 2007 · Past); Dyadic International, Inc. (Director · Feb 10, 2006 – Jan 2, 2007 · Past) | Director · Aug 7, 2013 – Mar 9, 2023 · Past |
All 42 people
| Person | Seat |
|---|---|
| Samuel Broder Other companies: Orion Biotech Opportunities Corp (Director · May 12, 2021 – May 17, 2023 · Past); Sensei Biotherapeutics, Inc. (Director · Feb 3, 2021 – Jul 10, 2023 · Past) | SVP, Head of Health Sector · Aug 7, 2013 – Jul 21, 2015 · Past |
| Suma Krishnan Other companies: Krystal Biotech, Inc. (President, Research & Development · Since at least Sep 19, 2017); New River Pharmaceuticals Inc (Vice President, Product Dev. · Mar 29, 2005 – Jan 25, 2007 · Past) | SVP--Product Development · Aug 7, 2013 – Jan 28, 2016 · Past |
| Thomas Bostick Other companies: CSX Corporation (Director · Since at least Oct 7, 2020); Perma-Fix Environmental Services, Inc. (Director · Since at least Aug 10, 2020) | Chief Operating Officer · Nov 27, 2017 – Jan 4, 2020 · Past |
| Cesar L. Alvarez Other companies: Watsco, Inc. (Director · Since at least Dec 31, 2021) | Director · Since at least Mar 3, 2021 |
| Helen Sabzevari Other companies: Kinnate Biopharma Inc (Director · Jun 24, 2021 – Apr 3, 2024 · Past) | President and CEO · Since at least Nov 27, 2017 |
| Jack A Bobo Other companies: AquaBounty Technologies, Inc. (Director · Dec 30, 2016 – Dec 30, 2016 · Past) | SVP, Chief Communications Off. · Jul 20, 2015 – Jul 20, 2015 · Past |
| Kelly Huang Other companies: Vyome Holdings, Inc. (Pres & Chief Executive Officer, Director · Sep 8, 2017 – Jan 2, 2019 · Past) | SVP-Consumer Sector · Mar 17, 2014 – May 9, 2014 · Past |
| Krish Krishnan Other companies: Krystal Biotech, Inc. (Chairman & CEO · Since at least Sep 19, 2017) | Chief Operating Officer · Aug 7, 2013 – Jan 28, 2016 · Past |
| Rick L Sterling Other companies: AquaBounty Technologies, Inc. (Director · Mar 10, 2021 – Jun 14, 2023 · Past) | Chief Financial Officer · Dec 15, 2020 – Jan 4, 2021 · Past |
| Steven R. Frank Other companies: BioCryst Pharmaceuticals, Inc. (Director · Since at least May 2, 2025) | Director · Since at least Aug 7, 2013 |
| Amy R. Lankford | SVP, Global Head of Regulatory Affairs · Since at least Nov 5, 2026 |
| Bryan T. Butman | SVP, Head of CMC · Since at least Nov 5, 2026 |
| Corey Huck | SVP, Food Sector · Oct 12, 2015 – Oct 12, 2015 · Past |
| D Bradford Osborne | VP, Finance and Accounting · Apr 2, 2021 – Apr 21, 2021 · Past |
| Donald Lehr | Chief Legal Officer · Since at least Aug 7, 2013 |
| Douglas E. Brough | SVP, Head of Research · Since at least Nov 5, 2026 |
| Ena Chan Cratsenburg | SVP, Consumer Sector · Jan 7, 2016 – Jan 7, 2016 · Past |
| Gaetano Bonifacio | SVP, Head of Development · Since at least Jan 20, 2026 |
| Harry Thomasian | Chief Financial Officer · Since at least Sep 24, 2026 |
| Harry Thomasian Jr | Chief Financial Officer · Since at least Oct 18, 2021 |
| James Vincent Lambert | Ex. Dir. Fin., PGEN Ther. Inc. · Jun 10, 2021 – Jun 10, 2021 · Past |
| Jeffrey Thomas Perez | SVP, IP Affairs · Dec 15, 2020 – Aug 9, 2024 · Past |
| Joel D Liffman | SVP, Finance · Jul 20, 2015 – Jan 4, 2019 · Past |
| Joseph L Vaillancourt | SVP, Environment Sector · Oct 19, 2015 – Oct 19, 2015 · Past |
| Nick Macris | VP--Environmental Sector · Aug 7, 2013 – Aug 7, 2013 · Past |
| Phil Tennant | Chief Commercial Officer · Since at least Jul 22, 2024 |
| Robert F Walsh III | SVP, Energy & Fine Chem. · Aug 7, 2013 – Jun 30, 2019 · Past |
| Rutul R. Shah | Chief Operating Officer · Since at least Jan 13, 2025 |
| Steven M. Harasym | Investor Relations · Since at least Nov 4, 2026 |
| Thomas R Kasser | SVP--Food Sector · Aug 7, 2013 – May 9, 2014 · Past |
| Trading S A Ares | Director · May 24, 2021 – May 24, 2021 · Past |
| Vinita D. Gupta | Director · Since at least Apr 25, 2017 |
Log in to ask 6ix AI your own questions about Precigen, Inc.